**Position statement**

**Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations**

Following publication of the Australasian Creatinine Consensus Working Group’s position statement in 2005 and revised statement in 2007, a number of issues have arisen, including the development of the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula for estimated glomerular filtration rate (eGFR) determination, revisions to CKD staging, use of eGFR in other ethnic groups and population groups (such as paediatric patients and pregnant women), use of eGFR for drug dosing, progress of creatinine assay standardisation and use of enzymatic assays. Consequently, the Australasian Creatinine Consensus Working Group convened in 2010 to consider these issues. The group consisted of 12 representatives nominated by the parent bodies of this process (Royal College of Pathologists of Australasia, Australasian Association of Clinical Biochemists, Royal Australian College of General Practitioners, Australian and New Zealand Paediatric Nephrology Association, Australian and New Zealand Society of Nephrology, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, and Kidney Health Australia). A larger stakeholder meeting of 31 participants was convened on 7 March 2011, with representatives from the aforementioned organisations as well as the Australian Practice Nurses Association, the Pharmaceutical Society of Australia, the Society of Obstetric Medicine of Australia and New Zealand, and the Kidney Health Australia National Consumer Council.

All evidence-based recommendations contained in this position statement are endorsed by the parent bodies of this process. It is also recommended that optimal screening for CKD and risk stratification of patients with CKD require careful evaluation of both eGFR and urinary albumin (see the recommendations of the Australasian Proteinuria Consensus Working Group).

**Recommendations**

1 Adoption of the CKD-EPI formula for calculating estimated glomerular filtration rate (eGFR)

A significant limitation of the Modification of Diet in Renal Disease (MDRD) “175” formula is that it suffers from imprecision and systematic underestimation of GFR at higher values (above 60 mL/min/1.73 m²). Recently, the CKD Epidemiology Collaboration developed a new CKD-EPI eGFR formula (Box) from a pooled dataset that included 10 studies and 8254 participants with and without known CKD (including participants with diabetes, potential kidney donors and transplant recipients). Validation of this formula in a separate external dataset of 3896 participants in 16 studies showed that the CKD-EPI formula retained the precision and accuracy of the MDRD formula at GFR < 60 mL/min/1.73 m², and showed less bias and improved precision at GFR > 60 mL/min/1.73 m². Subsequent epidemiological evaluations in North American and Australian general population studies have shown that the CKD-EPI equation more appropriately categorises individuals with respect to long-term clinical risks of end-stage kidney disease, coronary heart disease, stroke and all-cause mortality than the MDRD equation. In particular, 1.9% of the Australian Diabetes, Obesity and Lifestyle Study population was reclassified as not having CKD, and reclassified individuals were predominantly younger women with a favourable cardiovascular risk profile and absence of significant albuminuria. The CKD Epidemiology Collaboration studies used

**Summary**

- The publication of the Australasian Creatinine Consensus Working Group’s position statements in 2005 and 2007 resulted in automatic reporting of estimated glomerular filtration rate (eGFR) with requests for serum creatinine concentration in adults, facilitated the unification of units of measurement for creatinine and eGFR, and promoted the standardisation of assays. New advancements and continuing debate led the Australasian Creatinine Consensus Working Group to reconvene in 2010.

- The working group recommends that the method of calculating eGFR should be changed to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, and that all laboratories should report eGFR values as a precise figure to at least 90 mL/min/1.73 m².

- Age-related decision points for eGFR in adults are not recommended, as although an eGFR < 60 mL/min/1.73 m² is very common in older people, it is nevertheless predictive of significantly increased risks of adverse clinical outcomes, and should not be considered a normal part of ageing.

- If using eGFR for drug dosing, body size should be considered, in addition to referring to the approved product information. For drugs with a narrow therapeutic index, therapeutic drug monitoring or a valid marker of drug effect should be used to individualise dosing.

- The CKD-EPI formula has been validated as a tool to estimate GFR in some populations of non-European ancestry living in Western countries. Pending publication of validation studies, the working group also recommends that Australasian laboratories continue to automatically report eGFR in Aboriginal and Torres Strait Islander peoples.

- The working group concluded that routine calculation of eGFR is not recommended in children and youth, or in pregnant women. Serum creatinine concentration (preferably using an enzymatic assay for paediatric patients) should remain as the standard test for kidney function in these populations.
Formulas used for calculating eGFR*

**Abbreviated MDRD “175” formula**

\[ eGFR = \frac{175 \times (SCr \text{ in } \mu\text{mol/L} - 0.0113)^{-0.203} \times (0.742 \text{ if female})}{\text{age in years}^{0.993}} \]

**CKD-EPI formula**

- For females with SCr ≤ 62 μmol/L: \[ eGFR = 144 \times (SCr \text{ in } \mu\text{mol/L} - 0.0113)^{-0.320} \times 0.993^{\text{age in years}} \]
- For females with SCr > 62 μmol/L: \[ eGFR = 141 \times (SCr \text{ in } \mu\text{mol/L} - 0.0113)^{-0.320} \times 0.993^{\text{age in years}} \]
- For males with SCr ≤ 80 μmol/L: \[ eGFR = 144 \times (SCr \text{ in } \mu\text{mol/L} - 0.0113)^{-0.320} \times 0.993^{\text{age in years}} \]
- For males with SCr > 80 μmol/L: \[ eGFR = 141 \times (SCr \text{ in } \mu\text{mol/L} - 0.0113)^{-0.411} \times 0.993^{\text{age in years}} \]

*Coefficients for race are not included in these formulas. Note that these equations are only validated for use with isotope dilution mass spectrometry–traceable creatinine assays. eGFR = estimated glomerular filtration rate (mL/min/1.73m²). MDRD = modification of diet in renal disease. SCr = concentration of creatinine in serum. CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration.

Serum creatinine assays that were recalibrated, as required, to values aligned with the Roche enzymatic assay (Roche Diagnostics). As this assay has proven traceability to the isotope dilution mass spectrometry (IDMS) international reference method for creatinine measurement, the working group recommends that assays that are IDMS aligned (and otherwise suitable for the “175” MDRD equation) are suitable for routine use.

Changing from the MDRD formula to the CKD-EPI formula leads to higher eGFR values at normal or near-normal levels of kidney function, particularly in younger individuals (<60 years). Among older people of European ancestry (men > 70 years of age and women > 75 years), median eGFR estimates are lower for the CKD-EPI formula compared with the MDRD, although the magnitude of these differences is small.

It is important to recognise that improvements in the estimation of GFR achieved by the CKD-EPI formula do not ameliorate situations where creatinine-based GFR-estimating equations are typically limited, including severe malnutrition or obesity, extremes of body size or age, exceptional dietary intake (vegetarian diet or creatine supplements), skeletal muscle disease, paraplegia, limb amputations or rapidly changing kidney function.

Under such circumstances, GFR should be measured directly if there is doubt about whether kidney function is decreased. The use of the CKD-EPI formula also does not reduce the potential for creatinine assay interference by such substances as albumin, glucose, pyruvate, bilirubin, haemoglobin F and cephalosporins (especially cephalosporins). Where interferences are considered to be likely, especially in neonates, the use of an enzymatic method may be preferable.

**Recommendation:** The method of calculating eGFR should be changed to the CKD-EPI formula. (Evidence level, 1C)

**2 Reporting limit for eGFR using the CKD-EPI formula**

Given that the CKD-EPI equation is more accurate (predominantly due to reduced bias) than the “175” MDRD equation at higher levels of kidney function, the working group considered increasing the recommended reporting limit for eGFR. Although no consensus could be reached on this issue, the working group concluded that all laboratories should report eGFR values as a precise figure to at least 90 mL/min/1.73m².

**Recommendation:** All laboratories should report eGFR values as a precise figure to at least 90 mL/min/1.73m². (Evidence level, 1C)

**3 Serum creatinine assay performance in adult populations**

In Australia and New Zealand, routine use of serum creatinine assays that are IDMS traceable has significantly improved the between-laboratory difference in creatinine results. However, there are still differences in performance with regard to assay precision, variation from this standard, and interferences due to limitations in the analytical specificity of assays. To guide laboratories in selecting and running creatinine assays, it is necessary to have a quality standard for assay performance. The bias criterion of ±5% is the minimal standard based on a biological variation approach as proposed by the National Kidney Disease Education Program in the United States. A local evaluation of the effect of a 5% bias indicated that about 5% of general practice patients over 50 years of age having eGFR calculated would have their classification of stage of CKD changed at the level of 60 mL/min/1.73m² (GRD J, unpublished data, 2011). This criterion is a challenge for laboratories to meet, but is achievable with modern assays.

The effect of assay imprecision has relatively little effect on classification according to eGFR but can have a significant effect when monitoring serum creatinine concentration or eGFR in an individual. A coefficient of variation (CV) of 6.0% describes the average within-subject biological variation for serum creatinine (CVi), so an assay with a CV below 4.5% (0.75% of CVi) contributes less than an additional 25% to the total result variation. Better precision is preferred, but the benefits in clinical decision making are less marked. Most Australian and New Zealand laboratories can meet this specification at the creatinine concentrations found in adults.

**Recommendation:** The performance of serum creatinine assays should achieve a bias ±5% (ie, 5 μmol/L at a value of 100 μmol/L) and a long-term within-laboratory coefficient of variation (CV) less than 4% for the measurement of serum creatinine in adults. (Evidence level, 2C)

**4 Age-related reference intervals for eGFR in adults**

The Chronic Kidney Disease Prognosis Consortium recently published findings of collaborative meta-analyses of data from general and high-risk populations, and populations with kidney disease (45 cohorts in total, comprising 1,555,332 participants, summarised in Levey et al(1)). These data showed that eGFR < 60 mL/min/1.73m² was associated with increased risks of all-cause mortality, cardiovascular mortality, end-stage kidney disease, acute kidney injury and progression of CKD without consistent age interactions. In particular, for the controversial cate-
gory of eGFR 45–59 mL/min/1.73 m² with normal albuminuria, the relative hazards of all outcomes except all-cause mortality were similar above and below the age of 65 years in the general population cohorts. These observations are not consistent with the interpretation that decreased GFR with ageing is “normal” or “physiological”. Consequently, the working group concluded that age-related decision points for eGFR are not recommended in adults.

**Recommendation:** Age-related decision points for eGFR are not recommended in adults. *(Evidence level, 1C)*

### 5 The use of eGFR for adjusting drug dosing in patients with reduced kidney function

Renal drug clearance, which is usually proportional to GFR, is an important factor to consider when selecting a drug dose for a patient with CKD. Most official recommendations for drug dosing in kidney impairment are traceable to the manufacturers’ data by measured GFR or creatinine clearance estimated by the Cockcroft–Gault formula. Few studies have been conducted directly linking dosing according to eGFR with pharmacokinetic or clinical outcomes. However, eGFR provides a valid estimate of GFR and is widely available on laboratory reports. The units of eGFR are mL/min/1.73 m² whereas the units of drug clearance are mL/min. To avoid overdosing small patients or underdosing large patients, eGFR should be adjusted for patient size. In CKD, factors other than renal drug clearance can also alter drug effects. Thus, for drugs with a narrow therapeutic index, drug effects (desired and adverse) or drug concentrations should be monitored.

**Recommendation:** Dose reduction of some drugs is recommended for patients with reduced kidney function. Both eGFR (mL/min/1.73 m²) and estimated creatinine clearance (mL/min) provide an estimate of relative renal drug clearance. If using eGFR for drug dosing, body size should be considered, in addition to referring to the approved product information. For drugs with a narrow therapeutic index, therapeutic drug monitoring or a valid marker of drug effect should be used to individualise dosing. *(Evidence level, 1C)*

### 6 The use of eGFR in various ethnic populations

Both the MDRD and CKD-EPI formulae contain a factor to be applied to African Americans, raising the possibility that other variations in the formulae may be required for optimal performance in different ethnic groups. Indeed, several studies have shown that performance of the MDRD equation in China and Japan improved when population-specific coefficients were introduced. A recent study evaluated a GFR-estimating equation that incorporated a four-level race variable (black, Asian, Native American and Hispanic, and white and other) against CKD-EPI eGFR (incorporating a two-level race variable, African American or not) in a validation cohort of 4014 patients from 17 studies from the United States and Europe, as well as in 1022 patients from China, Japan and South Africa. The CKD-EPI equation showed minimal bias in black, Native American and Hispanic, and white and other ethnic subgroups, would be welcomed.

**Recommendation:** The validity of eGFR in pregnancy is not known. Serum creatinine concentration should be maintained as the standard test for kidney function in pregnant women, particularly in ethnic subgroups, would be welcomed. *(Evidence level, 1C)*

### 7 The use of eGFR in pregnancy

Significant physiological changes occur in normal pregnancy, some of which affect kidney function. However, studies of kidney function in normal pregnancy are limited, and may be non-existent in some ethnic populations. Kidney function changes throughout gestation, but becomes particularly important in medical disorders, such as pre-eclampsia, when reduced function may occur.

Validation studies of eGFR in pregnant women have not been performed. A 24-hour creatinine clearance, when the collection is complete, does provide a valid estimate of kidney function. Reference ranges for serum creatinine are available for the entire 40-week gestation, although the reference range will vary frequently, up to every 4 weeks. Additional studies to validate the use of eGFR as a measure of kidney function in pregnant women, particularly in ethnic subgroups, would be welcomed.

**Recommendation:** The validity of eGFR in pregnancy is not known. Serum creatinine concentration should be maintained as the standard test for kidney function in pregnant women. *(Evidence level, 1C)*

### 8 Measurement of serum creatinine concentration and calculation of eGFR in paediatric populations

There are limited and conflicting data on the value of routine screening for CKD in children and youth (individ-
uals aged less than 18 years). While a number of countries (predominantly within Asia) have instigated school-based screening programs, current publications have not convincingly shown that that early detection of kidney disorders in children will lead to a reduction in clinically significant outcomes. As such, the cost-effectiveness of such an approach has been questioned. Moreover, calculation of eGFR in children is logistically problematic because the most commonly used equation, the Schwartz formula, requires height data, which are not routinely measured at the time of blood collection. Thus, the working group does not recommend routine reporting of eGFR in children.

Creatinine production is a function of muscle mass and varies considerably throughout infancy and childhood as a result of growth and development. Serum creatinine concentration in normal infants and children increases with age and is slightly higher at any age in males than females. Normative values, obtained from studies that used creatinine assays that were traceable to the IDMS reference method have been published and are recommended for more accurate reporting of kidney function in children and adolescents. Although enzymatic and non-enzymatic methods are considered acceptable for measurement of creatinine in paediatric patients, enzymatic methods are generally preferred, particularly in young infants. Enzymatic methods are not affected by other substances (albumin, IgG and haemoglobin F) that are known to interfere with Jaffe creatinine assays and may lead to clinically important inaccuracies in the measurement of serum creatinine concentration. A detailed comparison of interferences in Jaffe and enzymatic creatinine assays has recently been published.

**Recommendation:** The use of an enzymatic assay is recommended for the measurement of serum creatinine concentration in children and youth (individuals aged less than 18 years). Other serum creatinine assays that achieve a bias < 10% at low serum creatinine values (ie, 5 µmol/L at a value of 50 µmol/L) and are not compromised by variations in albumin, bilirubin and haemoglobin F (neonates) would be satisfactory alternatives. Routine calculation of eGFR is not recommended in children and youth. Age-appropriate reference values for serum creatinine concentration should be reported for individuals up to 18 years of age. (Evidence level, 1C)

Conclusion

The available evidence indicates that introduction of automatic reporting of eGFR each time a test for serum creatinine concentration is requested has increased the awareness of significant kidney dysfunction in clinical practice, augmented the detection of patients with CKD in the community and enhanced the quantity of appropriate referrals to specialist renal services. It has also led to improvements in the accuracy and standardisation of laboratory measurement of creatinine and a reduction in the variability previously seen in Australasia and overseas. Progressive refinements in GFR estimating equations, from Cockcroft–Gault to “186” MDRD to “175” MDRD to CKD–EPI eGFR, have resulted in improved accuracy, particularly at normal and near-normal levels of kidney function, and in better kidney and cardiovascular risk prediction. However, clinicians should also be aware that there is now overwhelming evidence that optimal detection and subsequent risk stratification of CKD patients requires simultaneous consideration of both eGFR and urinary albumin, rather than eGFR alone.

**Competing interests:**

David Johnson has received consulting fees or honoraria from Amgen, Roche, Shire, Genzyme, Boehringer-Ingelheim, Baxter Healthcare and Fresenius Medical Care; support for travel to meetings from Baxter, Amgen, Roche and Shire; and payment for development of educational presentations from the Australian College of Rural and Remote Medicine and the Northern Territory Division of General Practice.

Graham Jones has received research support from Roche Diagnostics and support for travel to meetings from Roche Diagnostics and Bio-Rad.

Steven McTaggart has received funding for travel from Amgen, Roche and Janssen-Cilag.

**Provenance:** Not commissioned; externally peer reviewed.

8. Stevens LA, Schmid CH, Greene T, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) study equations for estimating GFR levels above 60 mL/min/1.73 m². Am J Kidney Dis 2010; 55: 468-495.


